Hematology Today—April 14, 2026

This week’s Hematology update highlights regulatory progress, long-term clinical durability data, evolving treatment access, and new guideline developments shaping patient care

Dive deeper

🧬 IASO Bio, Instituto Butantan partner on Brazil CAR-T localization [1] [10 Apr 2026]

https://en.iasobio.com/info.php?id=305
Context: IASO Bio said the agreement covers local development and manufacturing of autologous CAR-T cell therapy for hematological cancer in Brazil through Nutera-SP.
Key point: IASO Bio and Instituto Butantan announced a technology licensing deal aimed at expanding access and lowering cost through public-institution development.
Implication: Signals pipeline investment and modality expansion.

💊 Pharmac adds first-line CLL combinations in New Zealand [2] [New Zealand • 09 Apr 2026]

https://www.devdiscourse.com/article/health/3867469-pharmac-funds-new-cll-therapies-to-boost-blood-cancer-treatment
Context: Pharmac said funding begins 1 May 2026 for venetoclax plus ibrutinib and venetoclax plus obinutuzumab, with broader second-line access for ibrutinib.
Key point: New Zealand is moving targeted CLL combinations into first-line funded care, while also widening access to ibrutinib beyond initial treatment.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Hemlibra shows stronger bleed control than ITI in pediatric inhibitor-positive hemophilia A [3] [China • 10 Apr 2026]

https://hemophilianewstoday.com/news/hemlibra-outperforms-iti-controlling-bleeding-hemophilia-a-children-study/
Context: Retrospective single-center comparison at Beijing Children’s Hospital assessed Hemlibra versus immune tolerance induction in 140 children treated between 2020 and 2024.
Key point: Hemlibra prophylaxis was associated with better bleeding control, greater quality-of-life improvement, and lower medication cost than ITI, while not eradicating inhibitors.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 Roctavian posts five-year Phase 3 durability in severe hemophilia A [4] [07 Apr 2026]

https://hemophilianewstoday.com/news/most-men-hem-a-bleed-free-5-years-1-roctavian-dose/
Context: Final Phase 3 GENEr8-1 results covered men with severe hemophilia A after one Roctavian infusion, with follow-up through five years.
Key point: Roctavian maintained durable bleed reduction, reduced prophylaxis use, and improved quality of life in most treated men, with no new safety concerns reported.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Brexu-cel wins full FDA approval in relapsed or refractory mantle cell lymphoma [5] [10 Apr 2026]

https://www.targetedonc.com/view/brexu-cel-secures-full-fda-approval-in-r-r-mcl-reflections-from-zuma-2
Context: Targeted Oncology linked the decision to longer follow-up and added cohort data from the Phase 2 ZUMA-2 program in mantle cell lymphoma.
Key point: Brexucabtagene autoleucel (Tecartus; brexu-cel) moved from accelerated to full FDA approval in relapsed or refractory mantle cell lymphoma.
Implication: May influence prescriber choice and payer reviews pending full data.

📘 ASH and ISTH issue pediatric VTE prophylaxis guidance [6] [08 Apr 2026]

https://www.hematology.org/newsroom/press-releases/2026/ash-and-isth-guidelines-on-anticoagulant-prophylaxis-in-pediatric-vte
Context: The societies published joint clinical practice guidelines in Blood Advances for non-cardiac pediatric patients at risk of venous thromboembolism.
Key point: The guidance includes conditional recommendations against prophylaxis in some groups, and in favor of prophylaxis in selected groups such as antiphospholipid syndrome and long-term parenteral nutrition.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Brazil CAR-T localization could widen advanced-therapy access in a public-health setting, where imported cell therapy has been cost-prohibitive [1].
New Zealand’s CLL funding shift shows how payers are moving oral and targeted combinations earlier in care pathways, not just reserving them for relapse [2].
In hemophilia A, the contrast between Hemlibra and ITI highlights a practical trade-off between immediate bleed control and inhibitor eradication [3].
Roctavian’s five-year update adds longer-term durability evidence, which remains central for gene-therapy adoption, reimbursement, and treatment sequencing [4].
New pediatric VTE guidance from ASH and ISTH gives clinicians a more explicit framework in an area long shaped by extrapolation from adult data [6].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

FAQ

What did IASO Bio and Instituto Butantan actually announce?

They announced a technology licensing agreement to locally develop a CAR-T therapy for hematological cancer in Brazil. The source frames the goal as broader access and lower-cost public-sector delivery over time [1].

Which CLL regimens is Pharmac funding in New Zealand?

The source names venetoclax plus ibrutinib and venetoclax plus obinutuzumab as new first-line funded options from 1 May 2026. It also says access to ibrutinib will expand in second-line use [2].

Does the Hemlibra study mean ITI is no longer relevant?

No. The source says Hemlibra delivered better bleeding control and lower medication cost in this retrospective comparison, but it also notes Hemlibra does not eradicate inhibitors, unlike ITI [3].

What is the practical takeaway from the Roctavian five-year update?

The main message is durability. The source reports sustained bleed reduction, reduced prophylaxis use, and quality-of-life benefit through five years after one infusion, with no new safety concerns reported [4].

Why is full FDA approval for brexu-cel important in mantle cell lymphoma?

It converts an earlier accelerated approval into traditional approval, backed by longer follow-up and additional ZUMA-2 evidence. That can strengthen clinician confidence and treatment positioning in relapsed or refractory MCL [5].

What is new in the ASH and ISTH pediatric VTE guideline?

The guideline gives subgroup-specific recommendations for when to use or avoid anticoagulant prophylaxis in non-cardiac pediatric patients at risk of VTE. The source also highlights two good practice statements and a call for more risk-model research [6].

Entities / Keywords

IASO Bio, IASO Biotherapeutics, IASO Biopharma
Instituto Butantan, Butantan Institute, Nutera-SP
CAR-T, cell therapy, hematological cancer
Pharmac, New Zealand
CLL, chronic lymphocytic leukaemia, chronic lymphocytic leukemia
venetoclax, ibrutinib, obinutuzumab
Hemlibra, emicizumab
immune tolerance induction, ITI
hemophilia A, inhibitors
Roctavian, valoctocogene roxaparvovec, GENEr8-1
brexu-cel, brexucabtagene autoleucel, Tecartus
mantle cell lymphoma, MCL, relapsed/refractory MCL, R/R MCL
ZUMA-2
ASH, American Society of Hematology
ISTH, International Society on Thrombosis and Haemostasis
VTE, venous thromboembolism, anticoagulant prophylaxis, pediatrics